Ensign Peak Advisors
SGMO

Ensign Peak Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Ensign Peak Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-31,480
Closed -$154K – 2154
2022
Q3 		$154K Buy
31,480
+26,890
+586% +$138K ﹤0.01% 1966
2022
Q2 		$19K Hold
4,590
– – ﹤0.01% 2131
2022
Q1 		$27K Hold
4,590
– – ﹤0.01% 2163
2021
Q4 		$34K Buy
+4,590
New +$39.9K ﹤0.01% 2163
2020
Q3 		– Sell
-6,658
Closed -$60K – 1761
2020
Q2 		$60K Hold
6,658
– – ﹤0.01% 1656
2020
Q1 		$42K Sell
6,658
-7,658
-53% -$56.8K ﹤0.01% 1608
2019
Q4 		$119K Buy
+14,316
New +$132K ﹤0.01% 1642

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ensign Peak Advisors's SGMO Position: Q4 2022 in Review

Ensign Peak Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2022, closing a stake of 31,480 shares — an estimated $154K sold.

Ensign Peak Advisors first reported a position in SGMO in Q4 2019 and held it in 7 quarters. The position peaked at $154K in Q3 2022. 182 funds tracked by Wall St. Rank hold SGMO as of Q4 2022.

  • Ensign Peak Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 31,480 SANGAMO THERAPEUTICS INC shares in Q4 2022, an estimated $154K.
  • Ensign Peak Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q4 2019 and held it in 7 quarters.
  • Ensign Peak Advisors's SANGAMO THERAPEUTICS INC position peaked at $154K in Q3 2022.
  • 182 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.